Study S000748

A Repeat-dose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02683746
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 308
Start: 2016-03-16
Primary completion: 2017-04-03
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Lyophilized albiglutide DCC pen injector; DRUG:Lyophilized albiglutide DCC pen injector matching placebo; DRUG:Albiglutide liquid auto-injector; DRUG:Albiglutide liquid auto-injector matching placebo
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 [Baseline and Week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022858	Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus. Shaddinger BC, Diabetes research and clinical practice	2019	Randomized trial	PMID 31004676 DOI	registry reference BACKGROUND:31004676